Literature DB >> 24046272

IgA nephropathy factors that predict and accelerate progression to end-stage renal disease.

Lan Huang1, Feng-Ling Guo, Jin Zhou, Ya-Juan Zhao.   

Abstract

IgA nephropathy (IgAN) or Berger's disease is a slowly progressing disease that leads to end-stage renal disease in 50 % of the patients within 25 years of the disease. However, several factors are associated with the accelerated progression of this disease causing early development of end-stage disease. Persistent proteinuria or hematuria, poorly controlled hypertension, elevated serum creatinine and prevalent glomerulosclerosis are some of the risk factors that expedite the deteriorative effects of IgAN. Thus, the progression of the disease can be delayed if the associated risk factors are handled and addressed in the nick of time.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24046272     DOI: 10.1007/s12013-013-9741-2

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  4 in total

Review 1.  The Gut and Kidney Crosstalk in Immunoglobulin A Nephropathy.

Authors:  Luis Sanchez-Russo; Arun Rajasekaran; Sofia Bin; Jeremiah Faith; Paolo Cravedi
Journal:  Kidney360       Date:  2022-06-27

Review 2.  New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies.

Authors:  Dita Maixnerova; Delphine El Mehdi; Dana V Rizk; Hong Zhang; Vladimir Tesar
Journal:  J Clin Med       Date:  2022-05-16       Impact factor: 4.964

3.  Characterization of transgene expression and pDNA distribution of the suctioned kidney in mice.

Authors:  Natsuko Oyama; Yuki Fuchigami; Shintaro Fumoto; Megumu Sato; Masayori Hagimori; Kazunori Shimizu; Shigeru Kawakami
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy.

Authors:  Teodora Ioana Flavia Paunas; Kenneth Finne; Sabine Leh; Hans-Peter Marti; Tom Eirik Mollnes; Frode Berven; Bjørn Egil Vikse
Journal:  Clin Proteomics       Date:  2017-08-14       Impact factor: 3.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.